In the phase II NRG/RTOG 1122 trial, published in Cancer, the combination of bevacizumab (Avastin) and trebananib was found to be well tolerated; however, it did not significantly improve 6-month progression-free survival (PFS), PFS, or overall survival (OS) for patients with recurrent glioblastoma over bevacizumab alone.
Additionally, the shorter PFS observed in the experimental arm with a hazard ratio of 1.51 (P = 0.04) suggested that the addition of trebananib to bevacizumab is detrimental.
“Careful consideration should be given to future trials of [angiopoiein; Ang] inhibitors in combination with bevacizumab given the possible detrimental effects of Ang1 in this study,” the authors wrote. “Dual inhibitors of Ang2 and [vascular endothelial growth factor receptor; VEGFR] are in development and may have therapeutic potential for glioblastoma.”
In this study, patients…
